• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Farm bill signed into law; removes industrial hemp from Controlled Substance Act

January 31, 2019
Katie James, dvm360 Associate Content Specialist
dvm360, dvm360 March 2019, Volume 50, Issue 3

Cannabis sativa L no longer defined as illegal substance as long as products derived from it contain less than 0.3% THC.

Hemp, cannabidiol, CBD-regardless of what it's called, products containing compounds derived from the cannabis plant are a hot topic in both animal and human health for their potential benefits. But the murky legal status and regulations surrounding the flood of these products to the market make it difficult for veterinary practitioners to advise pet owners who may want to give them to their pet. That may soon change. 

In December, HR 2, the Agriculture Improvement Act of 2018, also known as the Farm Bill, was signed into law, and it includes provision to remove industrial hemp, or Cannabis sativa L, and its derivatives from the Controlled Substance Act. More specifically, products that contain compounds derived from the plant that contain less than 0.3 percent of tetrahydrocannabinol (THC), the psychoactive compound found in the plant, will be legal. Those that contain a higher percentage of THC will still be subject to Schedule I controlled substance regulations, according to an announcement about the bill from the AVMA. 

The bill notes that while it loosens the regulations for cannabis in the Controlled Substance Act, regulations established in the federal Food, Drug and Cosmetic Act and the Public Health Service Act have not been removed or altered, which will allow the FDA to still monitor label claims for products containing Cannabis sativa L and provide regulatory guidance. 

Curious about CBD?

Here are five quick Q&As with Stephen Cital, RVT, RLAT, SRA, VCCS and VTS-LAM, about the use of CBD in veterinary practice following passage of the Farm Bill.

Advertisement

The FDA released a lengthy statement from Commissioner Scott Gottlieb, MD, about the removal of the substance from the act, clarifying the agency's authority over products containing industrial hemp. 

“In short, we treat products containing cannabis or cannabis-derived compounds as we do any other FDA-regulated products-meaning they're subject to the same authorities and requirements as FDA-regulated products containing any other substance,” says Dr. Gottlieb in the statement.

He also discusses products not approved by the FDA that claim to contain cannabis-derived compounds, such as CBD. “Among other things, the FDA requires a cannabis product (hemp-derived or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into interstate commerce. This is the same standard to which we hold any product marketed as a drug for human or animal use.” 

Products containing cannabis-derived ingredients that claim to diagnose, mitigate, cure or prevent diseases are considered new drugs or new animal drugs and must go through the proper FDA drug approval process before they can be marketed to human or animal patients in the United States. Failure to follow this process is illegal, the statement notes. 

The agency plans to create clear pathways through its approval process for companies wishing to introduce new products into the marketplace. It also plans to hold a public meeting for stakeholders to discuss cannabis and its derivatives and its place in human and animal health, the statement concludes. 

“We recognize the potential opportunities that cannabis or cannabis-derived compounds could offer and acknowledge the significant interest in these possibilities. We're committed to pursuing an efficient regulatory framework for allowing product developers that meet the requirements under our authorities to lawfully market these types of products,” says Dr. Gottlieb.

What does this mean for practitioners? It just might mean that the next time a pet owner comes into your hospital asking for guidance on CBD chews for Max's osteoarthritis, you may not have to dance around the subject uncomfortably. As the AVMA puts it, “This has implications for the potential use of these products for a variety of purposes.” 

The AVMA has also created a quick sheet of all the animal health-related items in the Farm Bill, which can be accessed here. 

download issueDownload Issue: dvm360 March 2019

Related Content:

Pain ManagementMedicalRegulatoryLaw & EthicsBreaking Newsdvm360 March 2019
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Diagnostics for a thoracic trauma patient
Diagnostics for a thoracic trauma patient
Managing pain in the postoperative patient
Managing pain in the postoperative patient

Advertisement

Latest News

Zoetis announces Apoquel grant program

American Veterinary Medical Foundation welcomes new executive director

Details of new pet performance supplement line revealed

Veterinary scene Down Under: DEI advancements, plus title protection and more

View More Latest News
Advertisement